A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors

Trial Profile

A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Results (n=27) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top